Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ESR2 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intranasal, Intratumoral, Intralesional, Subcutaneous, Intrathecal, Parenteral
01
Overview
ESR2 siRNA is a small interfering RNA (siRNA) designed to target and silence the expression of the ESR2 gene, which encodes Estrogen Receptor beta (ERβ). By utilizing the RNA interference (RNAi) pathway, ESR2 siRNA facilitates the sequence-specific degradation of ESR2 mRNA, leading to a significant reduction in ERβ protein levels. In preclinical research, particularly concerning pulmonary hypertension (PH), ESR2 siRNA is used to investigate the regulatory role of ERβ in pulmonary arterial endothelial cells (PAECs). Studies have indicated that ERβ upregulation under hypoxic conditions contributes to the downregulation of the RNA editing enzyme ADAR1; silencing ESR2 with siRNA has been shown to restore ADAR1 levels, suggesting a potential therapeutic pathway for addressing vascular remodeling in PH.
- Other names
- ERβ siRNAESR2-directed siRNAESR-2-directed siRNAESR 2-directed siRNA
02
Targets
ESR2 (ERβ)
Beyond the preview
Go deeper on ESR2 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ESR2 siRNA.